BioCentury
ARTICLE | Clinical News

Opsumit improves right ventricular function in PAH patients

March 22, 2019 1:35 PM UTC

Actelion Ltd. said Opsumit macitentan significantly improved right ventricular function and pulmonary vascular resistance at week 26 compared with baseline in the open-label Phase IV REPAIR trial in patients with symptomatic pulmonary arterial hypertension.

The Johnson & Johnson (NYSE:JNJ) unit told BioCentury that based on final data from the trial expected this year, the company will evaluate "whether it is an option to add these data to our labeling and other opportunities within the diagnostic arena." The company noted that measurement of right ventricular function in PAH patients is helpful in monitoring response to treatment...

BCIQ Company Profiles

Actelion Ltd.

Johnson & Johnson

BCIQ Target Profiles

Endothelin receptor